{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:22:11Z","timestamp":1791296531873,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1124\/jpet.111.183780","type":"journal-article","created":{"date-parts":[[2011,7,8]],"date-time":"2011-07-08T10:47:19Z","timestamp":1310122039000},"page":"99-105","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":81,"title":["Antagonist Functional Selectivity: 5-HT2A Serotonin Receptor Antagonists Differentially Regulate 5-HT2A Receptor Protein Level In Vivo"],"prefix":"10.1016","volume":"339","author":[{"given":"Prem N.","family":"Yadav","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesley K.","family":"Kroeze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martilias S.","family":"Farrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan L.","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.111.183780_bib1","doi-asserted-by":"crossref","first-page":"7124","DOI":"10.1523\/JNEUROSCI.1090-09.2009","article-title":"PSD-95 is essential for hallucinogen and atypical antipsychotic drug actions at serotonin receptors","volume":"29","author":"Abbas","year":"2009","journal-title":"J Neurosci"},{"key":"10.1124\/jpet.111.183780_bib2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1146\/annurev-pharmtox-010510-100553","article-title":"Strategies to discover unexpected targets for drugs active at G protein-coupled receptors","volume":"51","author":"Allen","year":"2011","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1124\/jpet.111.183780_bib3","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1471-4159.1986.tb12944.x","article-title":"Differential effect of subchronic treatment with various neuroleptic agents on serotonin2 receptors in rat cerebral cortex","volume":"46","author":"Andree","year":"1986","journal-title":"J Neurochem"},{"key":"10.1124\/jpet.111.183780_bib4","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S0022-3565(25)31650-2","article-title":"Adrenergic and serotonergic receptor binding in rat brain after chronic desmethylimipramine treatment","volume":"209","author":"Bergstrom","year":"1979","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.111.183780_bib5","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S0026-895X(25)09230-2","article-title":"Rapid agonist-induced internalization of the 5-hydroxytryptamine2A receptor occurs via the endosome pathway in vitro","volume":"50","author":"Berry","year":"1996","journal-title":"Mol Pharmacol"},{"key":"10.1124\/jpet.111.183780_bib6","doi-asserted-by":"crossref","first-page":"8269","DOI":"10.1074\/jbc.M006968200","article-title":"The dynamin-dependent, arrestin-independent internalization of 5-hydroxytryptamine 2A (5-HT2A) serotonin receptors reveals differential sorting of arrestins and 5-HT2A receptors during endocytosis","volume":"276","author":"Bhatnagar","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.111.183780_bib7","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0022-3565(25)33057-0","article-title":"Serotonin receptor sensitivity after acute and chronic treatment with mianserin","volume":"221","author":"Blackshear","year":"1982","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.111.183780_bib8","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1126\/science.6278586","article-title":"Different synaptic location of mianserin and imipramine binding sites","volume":"215","author":"Brunello","year":"1982","journal-title":"Science"},{"key":"10.1124\/jpet.111.183780_bib9","doi-asserted-by":"crossref","first-page":"7321","DOI":"10.1073\/pnas.86.19.7321","article-title":"Antagonists with negative intrinsic activity at delta opioid receptors coupled to GTP-binding proteins","volume":"86","author":"Costa","year":"1989","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.111.183780_bib10","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1111\/j.1476-5381.1995.tb15954.x","article-title":"Behavioural interactions between 5-hydroxytryptophan, neuroleptic agents and 5-HT receptor antagonists in modifying rodent responding to aversive situations","volume":"116","author":"Costall","year":"1995","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.111.183780_bib11","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1126\/science.1103492","article-title":"The human polyomavirus, JCV, uses serotonin receptors to infect cells","volume":"306","author":"Elphick","year":"2004","journal-title":"Science"},{"key":"10.1124\/jpet.111.183780_bib12","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.tips.2007.06.005","article-title":"The evasive nature of drug efficacy: implications for drug discovery","volume":"28","author":"Galandrin","year":"2007","journal-title":"Trends Pharmacol Sci"},{"key":"10.1124\/jpet.111.183780_bib13","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0361-9230(01)00623-2","article-title":"Paradoxical trafficking and regulation of 5-HT2A receptors by agonists and antagonists","volume":"56","author":"Gray","year":"2001","journal-title":"Brain Res Bull"},{"key":"10.1124\/jpet.111.183780_bib14","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1124\/jpet.300.2.468","article-title":"Mechanisms of ligand-induced desensitization of the 5-hydroxytryptamine2A receptor","volume":"300","author":"Hanley","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.111.183780_bib15","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00213-003-1687-4","article-title":"Selective remodeling of rabbit frontal cortex: relationship between 5-HT2A receptor density and associative learning","volume":"172","author":"Harvey","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.111.183780_bib16","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1124\/jpet.111.180638","article-title":"The role of 5-hydroxytryptamine 7 receptors in the phencyclidine-induced novel object recognition deficit in rats","volume":"338","author":"Horiguchi","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.111.183780_bib17","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/BF00178504","article-title":"Down regulation of serotonin-S2 receptor sites in rat brain by chronic treatment with the serotonin-S2 antagonists: ritanserin and setoperone","volume":"88","author":"Leysen","year":"1986","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.111.183780_bib18","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/nn.2529","article-title":"CRF receptor 1 regulates anxiety behavior via sensitization of 5-HT2 receptor signaling","volume":"13","author":"Magalhaes","year":"2010","journal-title":"Nat Neurosci"},{"key":"10.1124\/jpet.111.183780_bib19","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0014-2999(97)01188-6","article-title":"MK-801-induced hyperlocomotion: differential effects of M100907, SDZ PSD 958 and raclopride","volume":"335","author":"Martin","year":"1997","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.111.183780_bib20","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1176\/appi.ajp.161.6.975","article-title":"Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder","volume":"161","author":"Meltzer","year":"2004","journal-title":"Am J Psychiatry"},{"key":"10.1124\/jpet.111.183780_bib21","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/npp.2009.176","article-title":"Pimavanserin, a serotonin2A receptor inverse agonist, for the treatment of Parkinson\u2019s disease psychosis","volume":"35","author":"Meltzer","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/jpet.111.183780_bib22","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/nrd1900","article-title":"Finding new tricks for old drugs: an efficient route for public-sector drug discovery","volume":"4","author":"O\u2019Connor","year":"2005","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/jpet.111.183780_bib23","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0022-3565(24)37870-X","article-title":"Effects of 5-hydroxytryptamine2 receptor antagonism on the behavioral activation and immediate early gene expression induced by dizocilpine","volume":"287","author":"O\u2019Neill","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.111.183780_bib24","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1126\/science.6251550","article-title":"Long-term antidepressant treatment decreases spiroperidol-labeled serotonin receptor binding","volume":"210","author":"Peroutka","year":"1980","journal-title":"Science"},{"key":"10.1124\/jpet.111.183780_bib25","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/S0026-895X(25)13451-2","article-title":"Repeated administration of SR 46349B, a selective 5-hydroxytryptamine2 antagonist, up-regulates 5-hydroxytryptamine2 receptors in mouse brain","volume":"43","author":"Rinaldi-Carmona","year":"1993","journal-title":"Mol Pharmacol"},{"key":"10.1124\/jpet.111.183780_bib26","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1126\/science.1150609","article-title":"GPCR engineering yields high-resolution structural insights into \u03b22-adrenergic receptor function","volume":"318","author":"Rosenbaum","year":"2007","journal-title":"Science"},{"key":"10.1124\/jpet.111.183780_bib27","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/nature09665","article-title":"Structure and function of an irreversible agonist-\u03b22 adrenoceptor complex","volume":"469","author":"Rosenbaum","year":"2011","journal-title":"Nature"},{"key":"10.1124\/jpet.111.183780_bib28","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0922-4106(91)90093-W","article-title":"Chronic mianserin treatment decreases 5-HT2 receptor binding without altering 5-HT2 receptor mRNA levels","volume":"207","author":"Roth","year":"1991","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.111.183780_bib29","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0024-3205(87)90621-7","article-title":"Multiple mechanisms of serotonergic signal transduction","volume":"41","author":"Roth","year":"1987","journal-title":"Life Sci"},{"key":"10.1124\/jpet.111.183780_bib30","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nrd1346","article-title":"Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia","volume":"3","author":"Roth","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/jpet.111.183780_bib31","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1476-5381.1956.tb00006.x","article-title":"A modification of receptor theory","volume":"11","author":"Stephenson","year":"1956","journal-title":"Br J Pharmacol Chemother"},{"key":"10.1124\/jpet.111.183780_bib32","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0006-8993(90)91015-9","article-title":"Pharmacological characterization of the behavioural syndrome induced by the NK-3 tachykinin agonist senktide in rodents: evidence for mediation by endogenous 5-HT","volume":"517","author":"Stoessl","year":"1990","journal-title":"Brain Res"},{"key":"10.1124\/jpet.111.183780_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/jpet.106.104463","article-title":"Functional selectivity and classical concepts of quantitative pharmacology","volume":"320","author":"Urban","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.111.183780_bib34","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/nature09746","article-title":"The structural basis for agonist and partial agonist action on a \u03b21-adrenergic receptor","volume":"469","author":"Warne","year":"2011","journal-title":"Nature"},{"key":"10.1124\/jpet.111.183780_bib35","first-page":"36","article-title":"Htr2a gene and 5-HT2A receptor expression in the cerebral cortex studied using genetically modified mice","volume":"4","author":"Weber","year":"2010","journal-title":"Front Neurosci"},{"key":"10.1124\/jpet.111.183780_bib36","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S0306-4522(98)00653-8","article-title":"Clozapine and other 5-hydroxytryptamine2A receptor antagonists alter the subcellular distribution of 5-hydroxytryptamine2A receptors in vitro and in vivo","volume":"91","author":"Willins","year":"1999","journal-title":"Neuroscience"},{"key":"10.1124\/jpet.111.183780_bib37","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1749-6632.1998.tb10182.x","article-title":"Serotonergic antagonist effects on trafficking of serotonin 5-HT2A receptors in vitro and in vivo","volume":"861","author":"Willins","year":"1998","journal-title":"Ann NY Acad Sci"},{"key":"10.1124\/jpet.111.183780_bib38","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S0306-4522(03)00589-X","article-title":"The PDZ-binding domain is essential for the dendritic targeting of 5-HT2A serotonin receptors in cortical pyramidal neurons in vitro","volume":"122","author":"Xia","year":"2003","journal-title":"Neuroscience"},{"key":"10.1124\/jpet.111.183780_bib39","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/npp.2010.195","article-title":"The presynaptic component of the serotonergic system is required for clozapine\u2019s efficacy","volume":"36","author":"Yadav","year":"2011","journal-title":"Neuropsychopharmacology"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235652446566X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235652446566X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.111.183780","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T21:36:03Z","timestamp":1740000963000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002235652446566X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S002235652446566X"],"URL":"https:\/\/doi.org\/10.1124\/jpet.111.183780","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antagonist Functional Selectivity: 5-HT2A Serotonin Receptor Antagonists Differentially Regulate 5-HT2A Receptor Protein Level In Vivo","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.111.183780","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2011 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}